Viemed Healthcare Inc

TSX:VMD

Earnings Call Transcript 2022-Q1

[Operator]

Greetings, and welcome to the Viemed First Quarter 2022 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the call over to Todd Zehnder, Chief Operating Officer. Thank you. You may begin.

[Todd Zehnder, executive]

Thank you, Darryl. Good morning, everyone. Please note that our remarks in this conference call may include forward-looking statements under the U.S. federal securities laws or forward-looking information under applicable Canadian securities legislation, which we collectively refer to as forward-looking statements.

Such statements reflect the company's current views and intentions with respect to future results or events and are subject to certain risks and uncertainties, which could cause actual results or events to vary from those indicated in forward-looking statements. Examples of such risks and uncertainties are discussed in our disclosure documents filed with the SEC or the securities regulatory authorities in certain provinces of Canada.

Because of these risks and uncertainties, investors should not place undue reliance on forward-looking statements. The forward-looking statements made in this conference call are made of -- as of today, and the company undertakes no obligation to update or revise any forward-looking statements, except as required by law. The first quarter financial news release, including the related financial statements, are available on the SEC's website.

I'll turn it over to Casey to get things started.

[Casey Hoyt, executive]

Thank you, Todd. Good morning, everyone. Thank you for joining our call today. We'd like to begin by acknowledging the dedicated team of respiratory therapists, behavioral health specialists, staffing professionals and administrative support staff who work tirelessly to deliver the best-in-class care to our patients living within the communities we serve.

As of March 31, our Viemed family of employees grew to 662. Compared to the same time last year, our total head count grew by over 25%. We continue to believe that our investments in and dedication to our people drive a unique company culture that ultimately helps differentiate our home delivery model from the competition. This has certainly contributed to our success in being able to acquire and develop good people amongst the battle for talent throughout the country.

As a result of this robust hiring growth, we were able to organically enter 4 new territories in the first quarter of 2022. Through our hands-on training programs, evolving middle management and a new recruiting platform inside of VieMed Healthcare Staffing, we are on our way to achieving the territory growth goals set at the beginning of the year.

In addition to the internal recruiting engine that VieMed Healthcare Staffing has provided, high contract demand and successful sourcing activities has resulted in an incredibly strong start to revenue-generating external services. In its first full quarter as an operating division, the experienced team that we built at VHS generated over $1 million in revenues. We are very optimistic about the growth and synergies that VieMed Healthcare Staffing contributes to our organization.

The geographic and service offering growth during the quarter was combined with exceptionally strong growth in our historic business activities. As the impact of the Omicron variant began to weaken early in the quarter, we finally witnessed a return to normal course of business with our referral sources. The increase in face-to-face interactions with patients and providers is contributing to strong momentum coming out of the pandemic.

A key differentiator in our service model is the level of high-touch personal care that we offer alongside of our products. We are well recognized in the respiratory care space as the benchmark for quality. Underlying our physical presence in the home is our best-in-class, high-tech, engaged technology platform now complemented by our behavioral health professionals.

As these differentiated services mature, we are capturing robust historical data that not only proves out our investment thesis but is also demonstrating to payers and providers that our care model contributes significant value in the evolving value-based care arena. Our traditional product lines benefit from the momentum exiting the pandemic constraints. We are incredibly excited to continue to innovate and expand our services to meet the evolving needs of patients, providers and payers.

In recent periods, our strong relationships with suppliers has been a critical success factor in times when competitors are unable to meet the needs of the patients and providers. As recalls and supply chain hurdles persist longer, Viemed has consistently obtained adequate resources to meet the demands of the market.

By preemptively investing in inventory and closely monitoring the supply chain, we were able to treat our existing population of patients and expand our market share by offering care when others were unable to do so. Unlike others in the industry, we never sat back and hope that supply chains would eventually catch up to our commitments to deliver care. We are establishing many new strong relationships with providers and referral sources whose existing suppliers are unable to meet their patients' current and future needs.

As a result, our CPAP and ancillary revenues continue to grow at an impressive rate, contributing to a meaningful diversification of our portfolio mix. We also believe that in the long term, our ability to meet these needs allows us to demonstrate the full suite of our capabilities to providers and referral sources.

Additionally, as a result of the increasing growth and diverse offerings, nonvent revenues now make up 28% of our core business.

Within the regulatory environment, we continue to see positive signs. The U.S. Department of Health and Human Services once again has renewed the public health emergency determination. Combined with the extension of moratorium relief for Medicare sequestration and 5.4% increase for 2022 to the Medicare fee schedule based on inflation, these positive reimbursement trends are mitigating the effects of increase in cost.

We're often asked about our views and expectations around the next possible round of competitive bidding in 2024. We've always maintained that it would be irresponsible to include life-saving devices such as noninvasive ventilators in the program. And we are also now seeing early indicators that the likelihood of a 2024 round becomes less likely as each month passes.

While the decision will be left to CMS, the historical inability to achieve desired savings and current delays in the initiation of potential upcoming competitive bidding programs are strong indicators that we will have the support from CMS to further expand our products and services to the home.

Further, we continue to invest in research that demonstrates the positive patient outcomes and cost savings associated with our products and services. A third study demonstrating the benefits of NIV has recently been submitted for peer review, and we are excited to formally share the detailed results upon publication.

We also continue to be methodical in our capital deployment strategies. During the end of the quarter, we were excited about the opportunity to repurchase shares and now have been executing on that buyback at what we see as an incredible value given the strength of our organization. Our M&A pipeline also remains active with signs that valuations are coming down to levels that are more in line with our established thresholds for return on investment.

Ultimately, our team views our risk assessment and capital strategies will allow us to be well positioned as the market evolves.

With more on our operations, financials, the buyback and regulatory landscape, I'll now turn the call back over to Todd Zehnder, our Chief Operating Officer.

[Todd Zehnder, executive]

All right. Thank you, Casey. In reviewing the financial results, all figures are in U.S. dollars and the full results have been made available on the SEC website as well as SEDAR.

Our core business generated net revenue of $30.2 million during the first quarter of 2022 as compared to net revenues of $25.5 million in the first quarter of 2021, which equates to an 18% increase. Our sequential growth for the core business was 4%. We have once again seen solid growth in our major product lines being vents, PAPs and oxygen.

During the first quarter, we generated approximately $2.1 million of revenue from our other sources, primarily the vaccine tracing revenue generated during the quarter with our call center. We still have an established unit in place at this time and can scale up or down in a very short period. Therefore, we will continue to pursue these opportunities in the future.

Our margin percentages, both gross and EBITDA, are once again very healthy and are primarily influenced by our core business. As our product lines continue to diversify, there might be some influence on these margin percentages, but the notional growth is the main priority for the business.

Our gross and EBITDA margins during the quarter came in at 61.2% and 22.5% accordingly. Our first quarter gross and EBITDA amounts came in at $19.7 million and $7.3 million, respectively.

We are once again encouraged by the rapid growth of our oxygen and sleep businesses as they continue to benefit from our ongoing national rollout of these products. Our first quarter revenue from vents was approximately 71% of our core revenue as compared to 80% in the first quarter of 2021. Importantly, our vent revenue has grown during the same time but the product diversification is beginning to show up more and more each quarter.

Our SG&A for the quarter totaled approximately $15.8 million as compared to $14.5 million in the first quarter of '21. We have seen some inflationary effects on SG&A, but have managed the expenses and preserved margins. We expect to continue hiring people to serve more patients around the country and expand our organic growth model to new areas.

As previously discussed, the need for traveling clinicians continues to abate, therefore, we have seen a decrease in the pressures on our people. We continue to seek out superior clinicians and professional folks to help support our business, which has always been the key to our successful organic efforts.

For the quarter, we invested approximately $4 million on capital expenditures. The CapEx was spread out across our product fleet as we have continued to grow all areas through a diversified supplier group. We have managed to stay in front of supply chain issues through strategic purchasing and feel comfortable that we will continue to have product to serve our growing patient base. This sometimes means that we buy in larger quantities and in certain cases, prepay for goods, but this is giving us the ability to increase market share.

We've once again funded all of our CapEx with discretionary cash flow, and we also strengthened the balance sheet during the quarter. At March 31, we had a cash balance of $29.3 million and an overall working capital of $30.1 million. Our total long-term debt remains at $4.3 million, and we have begun executing on our stock buyback. We once again have grown the company and stayed very underleveraged, which gives us the tools needed to significantly grow the company through all of our organic and inorganic efforts.

As mentioned, we began our buyback efforts on the previously disclosed Board-approved stock buyback. As of March 31, we had purchased 389,878 shares out of the total available of approximately 2 million shares under the plan. We were able to begin buying back on March 10 so we're off to a good start. As previously discussed, the buyback has risen in the ranks of our opportunities of capital deployment, but this does not mean that we are sacrificing business growth. We have continued to organically grow and are looking at inorganic opportunities and have been able to accomplish this while simultaneously reducing our share count.

Moving on to the OIG and CMS issue related to our NIV claims, we are continuing to work with CMS and its contractors through the appeal process to assess the medical necessity of the patients audited by OIG. As discussed on our last call, we filed with the QIC in the fourth quarter and are awaiting their final review of these claims. We anticipate receiving results back from this independent review during the next 30 days and are once again hopeful this round of review will have a more individualized clinical review.

Moving on to the second quarter. We've provided net revenue guidance in the $32.1 million to $32.8 million range related to our core business and have also guided approximately $200,000 to $300,000 of revenue related to the COVID-19 pandemic. Our organic core revenue is guided up 22% to 25% over the second quarter of 2021. We continue to be encouraged by the core revenue growth as we have seen the COVID effects diminish.

We have once again been visiting with current and prospective investors through the industry conferences and non-deal road shows with our existing analysts and banking relationships. We appreciate the ongoing support from both the buy and sell side during this year.

At this time, I'll turn it back over to Casey to wrap things up.

[Casey Hoyt, executive]

Thanks, Todd. To sum up the overall theme of the first quarter, I would say execution fueled by demand driven by return to normal course of business. I'm very proud of our management team as it specifically relates to the performance metrics on recruiting, acquiring and developing talent. I've watched our sequential improvement since the beginning of the pandemic on talent development and driving processes that help rapidly increase our organic growth.

At Viemed, we never take our eye off the ball as it relates to the growth strategies that got us to this point. We do, however, pay close attention to what the future holds. As I think about the strategies ahead for growing our business in a different way, I can categorize them into 4 buckets.

First, getting acquisitive with expanding our payer and geographical footprint, we know that our growth can be achieved in a faster way through finding companies that have different payer contracts with possibly different patient populations in areas that were not physically in just yet. While we don't have an acquisition report on yet, we continue to analyze these businesses and hope to execute on this strategy soon.

Second, hospital partnerships. Being in position to help drive the continuum of care from the facility to the home in the way that we are viewed as a valued partner. Initiatives are well underway to provide further solutions to our referral sources, allowing them to be in a position to treat a growing Medicare population of patients.

Third, [ as a vent ] solutions provider, we must be willing and nimble enough to offer solutions that have the highest demand for our referral partners. The staffing and behavioral health divisions are great examples of us providing this type of deliverable while still complementing our core business.

And lastly, business development through expansion of national payer contracts. As payers evolve into a more value-based world, has a clinically focused organization who can prove positive outcomes through the lens of data and -- through the lens of data technology, Viemed becomes an essential piece of the puzzle in treating large populations of patients in a way that saves money. These are the 4 areas of focus that will drive tremendous growth for Viemed and ultimately drive shareholder value in the future.

This concludes our prepared remarks. I want to thank everyone for taking time to join our call today and look forward to answering further questions. Thank you.

[Operator]

[Operator Instructions] Our first questions come from the line of Brooks O'Neil with Lake Street Capital Markets.

[Brooks O'Neil, analyst]

I have a couple of questions. I might have gotten distracted briefly in the middle of your prepared comments, which I thought were excellent, by the way, and very comprehensive. But I'm curious if you commented at all about the sort of the month-to-month progression that you saw during Q1 in the core business. And any comments you have relative to April would be extremely helpful.

[Todd Zehnder, executive]

No, you -- we did not make any comments about that, Brooks, but I can give you a little bit of additional info. I mean obviously, the first quarter began with Omicron affecting our country. And while it didn't swell up the hospital system, we had a bunch of employees and referring physicians that just went down with it.

So I would say that January and February were very much lighter than March, which is a good trend. And March and April, if you stack those on top of each other are the 2 best collective months that we've seen back-to-back since the pandemic began.

[Brooks O'Neil, analyst]

Great. I was hoping you'd say something like that. And it sounds like business is pretty much returned to normal, would you say, at the end of April?

[Todd Zehnder, executive]

I'd say yes. I mean it's as close to normal as we've seen, and I think we can't sit here and say that we're having a bunch of restrictions out there around the country. Have things changed some? Yes, I mean the whole world changed some, but are we back to where we think we can grow this company like we did prepandemic? Absolutely.

[Casey Hoyt, executive]

And I would just add to that and say that I've talked a lot about talent development and acquisition and training. The training programs that we evolved throughout the pandemic when we were kind of sitting on the bench, if you will, are really paying off right now. We're seeing a lot of our sales reps, whereas we would normally have 5 or 6 superstars per month. We're now seeing that we're having 11 and 12 show up, and it's a direct correlation in my mind to all of the development and training that we added along the way through Project Next Level, which we were talking a lot about last year. So we're seeing a lot of those efforts come to fruition.

[Brooks O'Neil, analyst]

Great, Casey. And I mean I took from your comments that you're not feeling constraints in your ability to hire the kind of respiratory therapists or other professionals or other team members that you need to aggressively grow the business going forward?

[Casey Hoyt, executive]

Not as it relates to the labor shortage or anything like that, it's -- we still have the same constraints that we always have, it's just finding the right people, the clinicians that we're often trying to convert into salespeople. But the good news is that VieMed Healthcare Staffing is proving out to be a great internal recruiting platform that's helping our sales managers be more efficient with just monitoring day-to-day things with the sales force and kind of taking recruiting out of their world. And that's proven to be very efficient and effective. And so these guys are still, I would consider, getting things going and haven't hit their complete stride just yet, but every day, it gets better and better. So I'm really excited about that infrastructure change that we made.

[Brooks O'Neil, analyst]

Great. Great. So you guys know I'm getting a little older, so I can sometimes not remember all the numbers that were in place prepandemic. But I kind of have a recollection that organic growth in the 30% to 35% range was kind of the target. Am I thinking about that right? And am I think -- is it reasonable to think that your goals would be to kind of try to get back there, recognizing that there have been changes in the business and as you scale, that kind of a number gets tougher?

[Todd Zehnder, executive]

I think those are all fair comments, Brooks, we were targeting in that 30% to 35% range. I'm not sure if we got it every quarter or every year that we -- pre the pandemic, but that is sort of what we wake up striving for. And I think the comment that the -- I'm not sure about the change in the business as much as just the law of bigger numbers becomes a little bit more difficult, but that doesn't mean that's not what we're striving for.

And look, we always go back to, I think, the number as of right now is 94% of what we define as the potential market is untapped. So there are plenty of patients who need our services, we've just got to continue to execute on going to find them.

[Brooks O'Neil, analyst]

Yes. That's great. Let me just ask you one more. I think I recall that you sort of quantified your exposure with this current OIG review in the range of sort of a maximum of $5 million. Again, am I remembering that correctly? And is that still kind of the sort of worst-case scenario you see for what's going on out there with those guys?

[Todd Zehnder, executive]

I got to correct you on that one. I can't call it your old age, you just probably had one slip up. It was actually a $9 million total exposure. And that continues to remain and like I said, we're hoping to get their review here, hopefully, in the next 30 days. That's kind of what we're anticipating, and we can update everybody at that point.

[Operator]

Our next questions come from the line of Nick Corcoran with Acumen Capital.

[Nick Corcoran, analyst]

I think Brooks asked most of the questions I have, but one thing that I don't think he asked earlier was the bad debt expense in the quarter was higher than the typical run rate. Can you maybe give a little bit of color on what happened in the quarter and what your expectation for the year will be?

[Todd Zehnder, executive]

Yes. Thanks, Nick. We -- look, we did take a higher bad debt percentage in this quarter. We have traditionally always said the first quarter is the most difficult with deductibles resetting and just new insurance plans and people changing insurance and so forth. So it's kind of the toughest time for us from a billing and collection standpoint. And now that we've been on a new workflow system for a period of time, we're getting better at looking at what our realizations and how much reserve we need.

So we took a higher percentage in the quarter. I would anticipate that our total annual percentage should remain the same, if not get better than last year. We have consistently, over the last few years, gotten probably 100 to 200 basis points better in our collection efforts. So I'm hopeful that, that happens. I'm pretty confident that the year-over-year bad debt will remain consistent. It's just that we we're going to be a little bit, I guess, more accurate on a quarterly basis.

[Nick Corcoran, analyst]

Great. And then your Q2 guidance shows strong year-over-year growth and sequential growth. How should we think about the remainder of the year? Like can you keep that growth up? Or do you think you will come down a bit?

[Todd Zehnder, executive]

That's obviously, it kind of ties into what Brooks' question was as well. We are hopeful that this sequential growth continues and if you do, you're starting to stack up. I think our midpoint was something around 6% to 8%. Our range was 6% to 8% sequential. If you do that, then you're on your way back up to that 25% to 35% growth range. That's not formal guidance. We don't have formal guidance out there, but we show up every day hoping to get back to those lofty ranges that we used to hit.

[Operator]

Our next questions come from the line of Doug Cooper with Beacon Securities.

[Doug Cooper, analyst]

Just getting back to the growth, it looks to my model, if you hit the sort of upper end of the range in Q2, it would be the best year-over-year growth quarter in the core business as Q1 2020. So yes, prepandemic. The year-over-year growth in vent patients this quarter was about 10% and core revenue growth up 18%. So diversification is working. What is the outlook for the increase in the vent patients in particular? I mean, obviously, you're doing a great job on the CPAP and oxygen and so forth.

[Casey Hoyt, executive]

It's no different than what we saw pre pandemic. I mean we -- like Todd mentioned, we're still after that underserved population, the 94% of folks that need us. We got to continue to get our studies out there that prove the mortality rates decreasing and the reduction in hospitalizations and ER visits, which are ultimately leading to savings. All that science and data that we've developed is going to be key in really moving the market penetration needle. But our game to get to the [ VIP ] business is no different as it relates to finding people, getting them in good areas, getting them up and running and trained to walk and talk the Viemed way.

I'd like to think that hospital partnerships and really getting inside of the hospital and becoming more of an extension of their continuum of care is the next way to really hit the core business in a different way. And so we're in the midst of those kinds of discussions.

And certainly, the ability to use staffing as a lead in to help our hospital partners is key right now because they're just yearning for more clinical staff. We're able to help. And then the next conversation is, okay, well, we're helping here in staffing, but how can we further help you into the home with treating these respiratory patients in a unique way. And so that's going to be something that we really try to hone in on and focus on in 2022. And we hope that just ends up being another organic growth strategy.

[Doug Cooper, analyst]

Casey, you mentioned that you're -- you kind of went into 4 new territories in Q1, and you're on track in your goals. Can you just remind us what is the goals for new territories this year?

[Casey Hoyt, executive]

I believe we said 25 last quarter is the new goal. It's either 20 or 25, but we're looking good on that as we sit here in April 2. We're increasing our rate from the first quarter, and so we hope to stay on track for that. But last year, the incremental number was 5, Doug. So the fact that we added 4 in the first quarter is a good sign that we're on track to hit that goal or pretty close at least.

[Doug Cooper, analyst]

Okay. And can you give us an idea of your -- so you hit the goal of 20, 25 new territories. What would be your geographical penetration of the U.S. at that point? Just to give us an idea.

[Casey Hoyt, executive]

It's -- we're in 45 states with where our respiratory therapists have patients, and we're treating patients. And that's kind of how we highlight the state. But again, we're not in New York, and I'll just use that as an example. But it's not on the top of mind to get into New York. We can classify a new area in a state that we have really good coverage, but it's 60 miles down the road, but it is an incremental new area with a new rep, a new set of respiratory therapies, new hospital system. It's basically like starting up a new business.

And we made that change at the beginning of the year to not talk about just where we're hiring reps because reps can come and go, but that area, that incremental new business area is the way that we want to start reporting it. Because just because the rep comes and goes, it doesn't mean that we can't sustain and maintain in a new area.

And so I think it's the right way for you guys to think about how we're growing versus just tracking our new hires. Those sales reps do so many different things. We have hunters, we have farmers, we have assistant sales reps and so on and so forth. So it's just -- it wasn't right just tracking it that way. It's better to just watch it for new areas.

[Todd Zehnder, executive]

And I'll add one other context is that like in the case of states, we used to talk about states in a lot of detail and so forth. And when we -- just to put it in context, I think we have 8 sales reps in the state of Louisiana. I think we have one in California. So calling those that were in both of those states, we know that there's a ton of runway in California, right, just because of the pure size and population.

So Casey is right. We're serving patients, I think, in 45, but the density that we have available to us in those states is just tremendous.

[Doug Cooper, analyst]

Okay. And does that correspond to say like you get a national payer contract, is that kind of easier entry in this or expansion or entry into some of those areas you're not in?

[Todd Zehnder, executive]

Yes, it's always easier to go into a state when you've got good contracts already. It just gives the -- it gives the sales force so much more ability to impact patients' lives and to take all patients from referral sources, and that's always a challenge. So as we move into state, it does take us some time to get our model out there and to get new insurance contracts, but we've done pretty good at doing that over time.

[Doug Cooper, analyst]

Okay. My last one for me. Todd, you said you started buying stock back March 10, is that right?

[Todd Zehnder, executive]

Yes, that was the date that we were able to go live.

[Doug Cooper, analyst]

Okay. And what was the average price of the stock that you bought back? Do you have that?

[Todd Zehnder, executive]

I don't have it. I know it's in the filing. I think through March -- I mean, through March 31, it was like $4.75, $4.85, something like that.

[Doug Cooper, analyst]

Okay. And have you continued to buy stock back in this quarter?

[Todd Zehnder, executive]

We do. It was actually $4.84. I just saw the number, $4.84 for the average, and we have -- we continue to buy -- I can't give numbers yet. I have to give them at the end of the quarter, but we've pretty much been buying every day.

[Operator]

Our next questions come from the line for Prasath Pandurangan.

[Prasath Pandurangan, analyst]

I just have the one unanswered. Could you talk about the margin structure and growth prospects for the staffing solutions business related to the core business?

[Todd Zehnder, executive]

The staffing margins currently, we're running -- I don't have an exact EBITDA margin, but I think it is accretive to the business currently. And it really depends on the type of contracts we have. I think over time, as we become more of a traditional or a piece of the business becomes more traditional staffing, it could be running at a lower EBITDA margin than the core business. But thus far, because we've been more of what I guess would be defined as placement revenue generation and more of just a fee-based business instead of just gross salaries and expenses, it has been accretive thus far. So we don't have a complete breakout just yet, but I do know that it did a little bit over $1 million of top line revenue for the quarter.

[Operator]

Our next questions come from the line of Brooks O'Neil with Lake Street Capital Markets.

[Brooks O'Neil, analyst]

Sorry, guys. I was listening to Doug's question and it occurred to me, I'm not sure I know the number of total business areas you're in. And I can imagine -- and I'm not this kind of a modeling guy myself, but I can imagine that 60 miles down the road from New York City, there's a lot of people. 60 miles down the road from some place in rural Louisiana, there might not be that many people. But how do you think about the number of territories you have? And any way you think about what's left to go after out there?

[Todd Zehnder, executive]

We're going to have to get back to you on that, Doug. I think the number is in the 60s right now. And it's not like we're not disclosing. We just -- we don't have it in front of us. But we've got probably about 80 total sales reps if I had to guess, and some of those are like in one area. So it's probably mid-60s. And we'll just have to get -- ping you later off-line.

[Operator]

There are no further questions at this time. I would now like to turn the call back over to Casey Hoyt for any closing comments.

[Casey Hoyt, executive]

Well, thanks, everyone, for joining the call. We appreciate all of your thoughtful questions and look forward to continuing to drive shareholder value. Have a nice day.

[Operator]

This does conclude today's teleconference. We appreciate your participation. You may disconnect your lines at this time. Enjoy the rest of your day.